{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 31,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a three-column layout to summarize clinical trial safety data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/24",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.06,
        "y": 0.78
      },
      "kind": "callout",
      "text": "No additional toxicities were reported in combination with pembrolizumab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2006a9c-39ce-4d82-8eb8-bbcbdc01f3bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.66,
        "y": 0.22
      },
      "kind": "list",
      "text": "DLTs at MTD: Three DLTs reported at 6 mg q7d and 10 mg q21d; manageable with standard care.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1af11841-4783-4f1c-bf65-95055dac938c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.36,
        "y": 0.22
      },
      "kind": "list",
      "text": "Most Commonly Reported AEs at RP2D Monotherapy: 3 mg q7d (n=7) and 6 mg q21d (n=8) safety profiles, including Grade 3-4 TRAEs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8af5aceb-fd5b-4062-9323-4a5b7c1a2b56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "list",
      "text": "RP2D Regimens Selected: SC 3 mg q7d declared as RP2D; 6 mg q21d dose flexibility; MTD determined as 6 mg q7d and 10 mg q21d.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df0895fc-d3ed-4c06-8a3f-cb77728b3a38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "AEs: Adverse Events; ALT/AST: aspartate aminotransferase / alanine aminotransferase; TRAEs: Treatment-related adverse events; DLTs: Dose-limiting toxicities; MTD: Maximum tolerated dose; RP2D: Recommended phase 2 dose; SC: Subcutaneous, IV: Intravenous",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "243c7d0e-98b0-45be-ad49-a9c3ce052e08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.85,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Data as of March 19. 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fa0bdfe-2fa3-4be2-9584-fcd55ef9ce68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Safety Profile of Subcutaneous Nemvaleukin Consistent With Mechanism of Action and IV Nemvaleukin",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3135461-7dbb-493c-bc70-8b9d16483331",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 22,
      "beatId": "6729dbcf-9af8-4183-a612-b8bbf1c1b0a8",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The presentation concludes with a summary of results and a panel discussion",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}